George Bakris to Hyperkalemia
This is a "connection" page, showing publications George Bakris has written about Hyperkalemia.
Connection Strength
7.426
-
Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94.
Score: 0.729
-
Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabet Med. 2018 08; 35(8):1049-1050.
Score: 0.637
-
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3.
Score: 0.608
-
Current and future potassium binders. Nephrol News Issues. 2016 Apr; 30(4):suppl 27-31.
Score: 0.542
-
Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015; 16(14):2205-15.
Score: 0.521
-
New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015 Oct; 66(4):731-8.
Score: 0.520
-
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
Score: 0.516
-
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3):333-9.
Score: 0.473
-
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
Score: 0.344
-
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
Score: 0.200
-
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81.
Score: 0.193
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
Score: 0.186
-
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 09; 75(22):2836-2850.
Score: 0.181
-
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
Score: 0.157
-
Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55.
Score: 0.143
-
Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016 Jul; 18(7):56.
Score: 0.138
-
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
Score: 0.138
-
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51.
Score: 0.136
-
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65.
Score: 0.131
-
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
Score: 0.130
-
New agents for hyperkalemia. N Engl J Med. 2015 04 16; 372(16):1570-1.
Score: 0.127
-
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
Score: 0.123
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
Score: 0.115
-
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
Score: 0.086
-
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010 Oct 29; 144(3):383-8.
Score: 0.084
-
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
Score: 0.081
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75.
Score: 0.059
-
Cardiology patient page. Kidney failure and cardiovascular disease. Circulation. 2003 Oct 21; 108(16):e114-5.
Score: 0.057
-
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13; 160(5):685-93.
Score: 0.045
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95.
Score: 0.026